Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Mr. Gregory O. MalcolmExec. VP & Controller | -2,30k | 203,41k | Vente | 88,44 | 22,20k | -9,39% |
| 2026-05-07 | Ms. Sally MasseyChief HR Officer | -8,60k | 751,63k | Vente | 87,41 | 21,94k | -28,16% |
| 2026-02-23 | Mr. John HazlinChief Growth Officer | -6,12k | 593,96k | Sale to Issuer | 97,10 | 29,87k | -17,00% |
| 2026-02-23 | Ms. Jennifer M. DanielsVice Chair | -12,35k | 1,20M | Sale to Issuer | 97,10 | 91,68k | -11,87% |
| 2026-02-23 | Mr. Stanley J. SutulaCFO | -19,75k | 1,92M | Sale to Issuer | 97,10 | 74,65k | -20,92% |
| 2026-02-23 | Mr. Gregory O. MalcolmExec. VP & Controller | -2,26k | 219,45k | Sale to Issuer | 97,10 | 24,45k | -8,46% |
| 2026-02-23 | Ms. Sally MasseyChief HR Officer | -8,21k | 796,80k | Sale to Issuer | 97,10 | 30,50k | -21,20% |
| 2026-02-23 | Mr. Panagiotis TsourapasCOO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | -13,08k | 1,27M | Sale to Issuer | 97,10 | 88,44k | -12,89% |
| 2026-02-23 | Mr. Noel R. WallaceChairman, CEO & President | -68,25k | 6,63M | Sale to Issuer | 97,10 | 468,54k | -12,71% |
| 2026-02-11 | Mr. Panagiotis TsourapasCOO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | -50,00k | 957,94k | Derivative Exercise and Sale | 76,41 - 97,81 | 75,73k | - |
| 2026-02-10 | Mr. John HazlinChief Growth Officer | -20,99k | 374,44k | Derivative Exercise and Sale | 76,41 - 94,25 | 23,10k | - |
| 2026-02-06 | Mr. Gregory O. MalcolmExec. VP & Controller | -12,75k | 235,82k | Derivative Exercise and Sale | 76,41 - 94,91 | 20,43k | - |
| 2026-02-05 | Ms. Sally MasseyChief HR Officer | -15,85k | 295,11k | Derivative Exercise and Sale | 76,41 - 95,03 | 21,86k | - |
| 2026-02-04 | Mr. Stanley J. SutulaCFO | -97,84k | 1,22M | Derivative Exercise and Sale | 81,78 - 94,27 | 55,64k | - |
| 2026-02-04 | Ms. Jennifer M. DanielsVice Chair | -22,00k | 485,02k | Derivative Exercise and Sale | 72,29 - 94,34 | 78,24k | - |
| 2026-02-04 | Mr. Noel R. WallaceChairman, CEO & President | -45,57k | 4,28M | Vente | 93,91 | 399,80k | -10,23% |
| 2025-12-03 | Mr. Stanley J. SutulaCFO | -385,00 | 30,11k | Sale to Issuer | 78,20 | 55,64k | -0,69% |
| 2025-12-03 | Mr. Noel R. WallaceChairman, CEO & President | -1,31k | 102,21k | Sale to Issuer | 78,20 | 445,01k | -0,29% |
| 2025-12-03 | Mr. Panagiotis TsourapasCOO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | -221,00 | 17,28k | Sale to Issuer | 78,20 | 75,70k | -0,29% |
| 2025-12-03 | Mr. John HazlinChief Growth Officer | -156,00 | 12,20k | Sale to Issuer | 78,20 | 23,06k | -0,67% |
| 2025-12-03 | Mr. Gregory O. MalcolmExec. VP & Controller | -41,00 | 3,21k | Sale to Issuer | 78,20 | 20,38k | -0,20% |
| 2025-12-03 | Ms. Jennifer M. DanielsVice Chair | -213,00 | 16,66k | Sale to Issuer | 78,20 | 78,23k | -0,27% |
| 2025-11-21 | Ms. Sally MasseyChief HR Officer | -1,24k | 100,06k | Vente | 80,89 | 21,81k | -5,37% |
| 2025-09-12 | Ms. Jennifer M. DanielsVice Chair | -1,42k | 118,34k | Sale to Issuer | 83,28 | 78,37k | -1,78% |
| 2025-09-12 | Mr. Panagiotis TsourapasCOO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | -1,42k | 118,34k | Sale to Issuer | 83,28 | 75,83k | -1,84% |
| 2025-09-12 | Mr. Stanley J. SutulaCFO | -2,14k | 177,89k | Sale to Issuer | 83,28 | 55,92k | -3,68% |
| 2025-09-12 | Ms. Prabha ParameswaranInitié | -1,68k | 139,74k | Sale to Issuer | 83,28 | 63,78k | -2,56% |
| 2025-09-12 | Ms. Sally MasseyChief HR Officer | -1,12k | 92,94k | Sale to Issuer | 83,28 | 22,95k | -4,64% |
| 2025-09-12 | Mr. Gregory O. MalcolmExec. VP & Controller | -241,00 | 20,07k | Sale to Issuer | 83,28 | 20,35k | -1,17% |
| 2025-09-12 | Mr. John HazlinChief Growth Officer | -826,00 | 68,79k | Sale to Issuer | 83,28 | 23,01k | -3,47% |
| 2025-09-12 | Mr. Noel R. WallaceChairman, CEO & President | -7,75k | 645,34k | Sale to Issuer | 83,28 | 445,61k | -1,71% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
